This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leal-Cerro, A. Articles by Dieguez, C. Search for Related Content PubMed PubMed Citation Articles by Leal-Cerro, A. Articles by Dieguez, C.

The Growth Hormone (GH)-Releasing Hormone - GH - Insulin-like Growth Factor-1 Axis in Patients with Fibromyalgia Syndrome¹

Department of Endocrinology (A.L.-C., R.A., H.S., F.G.-P.) and Reumatology (J.P., M.G.), Hospital Universitario "Virgen del Rocio", 15700 Sevilla; and Departments of Medicine (F.F.C.) and Physiology (C.D.), Complejo Hospitalario Universitario and Faculty of Medicine, University of Santiago, 15700 Santiago de Compostela Spain

Address all correspondence and requests for reprints to: C. Dieguez, P.O. Box 563, 15700 Santiago de Compostela, Spain. E-mail: fscadigo{at}uscmail.usc.es

Fibromyalgia (FM) is a painful syndrome of nonarticular origin, characterized by fatigue and widespread musculoskeletal pain, tiredness, and sleep disturbances, without any other objective findings on examination. Interestingly, some of the clinical features of FM resemble the ones described in the adult GH-deficiency syndrome. Furthermore, insulin-like growth factor (IGF)-1 levels are frequently reduced in patients with FM. To gain further insight into the mechanisms leading to dysregulation of the GH-IGF-1 axis in these patients, we assessed 24-h spontaneous GH secretion, GH responses to GHRH, and IGF-1 and IGF binding protein (BP)-3 levels before and after 4 days treatment with human (h)GH.

We found that, in comparison with controls, patients with FM exhibited a marked decrease in spontaneous GH secretion as assessed by mean GH secretion (2.5 ± 0.4 µg/L in controls vs. 1.2 ± 0.1 µg/L in FM, P < 0.05), pulse height (4.7 ± 0.8 µg/L in controls vs. 2.5 ± 0.3 µg/L in FM, P < 0.05), and pulse area (4.7 ± 1 min/mg·L in controls vs. 2.3 ± 0.3 min/mg·L in FM, P < 0.05). In contrast, GH responses to GHRH (100 µg, iv) were similar in controls (mean peak, 13.5 ± 2.5 µg/L) and in patients with FM (12.2 ± 3 µg/L). Finally, treatment with hGH (2 IU, sc daily), over 4 days, led to a clear-cut increase in plasma IGF-1 and IGFBP-3 levels in patients with FM.

In conclusion, our data show that patients with FM exhibited a marked decrease in spontaneous GH secretion, but normal pituitary responsiveness to exogenously administered GHRH, thus suggesting the existence of an alteration at the hypothalamic level in the neuroendocrine control of GH in these patients. Furthermore, our finding of increased IGF-1 and IGFBP-3 levels after GH treatment, over 4 days, opens up the possibility of testing the therapeutic potential of hGH in patients with FM.

This article has been cited by other articles:

				J. Bonnefont, L. Daulhac, M. Etienne, E. Chapuy, C. Mallet, L. Ouchchane, C. Deval, J.-P. Courade, M. Ferrara, A. Eschalier, et al. Acetaminophen Recruits Spinal p42/p44 MAPKs and GH/IGF-1 Receptors to Produce Analgesia via the Serotonergic System Mol. Pharmacol., February 1, 2007; 71(2): 407 - 415. [Abstract] [Full Text] [PDF]

				C. A. Landis, M. J. Lentz, J. Rothermel, S. C. Riffle, D. Chapman, D. Buchwald, and J. L. F. Shaver Decreased Nocturnal Levels of Prolactin and Growth Hormone in Women with Fibromyalgia J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1672 - 1678. [Abstract] [Full Text]